Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study

doi:10.3748/wjg.v23.i19.3513

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 19

This Article

(381)

(360)

(0)

(8749)

(17)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Observational Study

World J Gastroenterol. May 21, 2017; 23(19): 3513-3521
Published online May 21, 2017. doi: 10.3748/wjg.v23.i19.3513

Table 1 Baseline characteristics of the selective serotonin reuptake inhibitor cohort and the non-selective serotonin reuptake inhibitor cohort, 2000-2010 n (%)

Variable	SSRI use		P value
Variable	No (n = 78612)	Yes (n = 19653)	P value
Sex			1.000
Female	45984 (58.5)	11496 (58.5)
Male	32628 (41.5)	8157 (41.5)
Age, yr			1.000
< 20	5548 (7.1)	1387 (7.1)
20-29	11592 (14.8)	2898 (14.8)
30-39	14312 (18.2)	3578 (18.2)
40-49	15112 (19.2)	3778 (19.2)
50-59	11720 (14.9)	2930 (14.9)
≥ 60	20328 (25.9)	5082 (25.9)
Urbanization¹			< 0.001
1	24102 (31.3)	6275 (32.7)
2	23134 (30.0)	5851 (30.5)
3	12486 (16.2)	2827 (14.7)
4	17325 (22.5)	4228 (22.0)
Family income (NTD)			< 0.001
0	13932 (17.7)	3411 (17.4)
1-15840	14871 (18.9)	4807 (24.5)
15841-28800	33687 (42.9)	7915 (40.3)
28801-45800	10243 (13.0)	2173 (11.1)
≥ 45801	5874 (7.5)	1346 (6.9)
Area			< 0.001
North	39708 (50.6)	10001 (51.0)
Midland	14067 (17.9)	3265 (16.7)
South	22823 (29.1)	5642 (28.8)
East	1837 (2.3)	690 (3.5)
Occupation			< 0.001
Public and military	5735 (8.2)	1531 (8.8)
Industry	23168 (33.3)	5617 (32.3)
Business	28266 (40.6)	5841 (33.6)
Low income	559 (0.8)	385 (2.2)
Other and retired	11898 (17.1)	3994 (23.0)
Anti-psychotics			< 0.001
No	75615 (96.2)	16022 (81.5)
Yes	2997 (3.8)	3631 (18.5)
Comorbidity
Diabetes mellitus	8126 (10.3)	3143 (16.0)	< 0.001
Hypertension	18319 (23.3)	6726 (34.2)	< 0.001
Hyperlipidemia	11823 (15.0)	4521 (23.0)	< 0.001
Colorectal cancer	290 (0.4)	96 (0.5)	0.017
Major depressive disorder	770 (0.98)	4274 (21.8)	< 0.001
Anxiety disorder	10007 (12.7)	9477 (48.2)	< 0.001
Bipolar disorder	130 (0.2)	273 (1.4)	< 0.001
Posttraumatic stress disorder	7 (0.0)	101 (0.5)	< 0.001
Eating disorder	26 (0.0)	141 (0.7)	< 0.001
Mean follow-up time (yr)	5.86 ± 3.00	5.53 ± 3.21

¹Urbanization level: 1 indicates the highest level of urbanization and 4 the lowest. SSRI: Selective serotonin reuptake inhibitor; NTD: New Taiwan dollars.

Full Size Table

Citation: Lin WT, Liao YJ, Peng YC, Chang CH, Lin CH, Yeh HZ, Chang CS. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J Gastroenterol 2017; 23(19): 3513-3521
URL: https://www.wjgnet.com/1007-9327/full/v23/i19/3513.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i19.3513

Lin WT, Liao YJ, Peng YC, Chang CH, Lin CH, Yeh HZ, Chang CS. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J Gastroenterol 2017; 23(19): 3513-3521 [PMID: 28596687 DOI: 10.3748/wjg.v23.i19.3513]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.